Literature DB >> 3292101

Drugs in human milk. Clinical pharmacokinetic considerations.

H C Atkinson1, E J Begg, B A Darlow.   

Abstract

Drugs ingested by a lactating mother would be expected to appear in human milk to some extent and be ingested by a breast-feeding infant. Drugs pass from maternal plasma into milk by passive diffusion and are distributed within the aqueous, protein and lipid phases of milk. Distribution into milk will be affected by physiochemical characteristics of the drug: acid-base characteristics, relative protein binding in plasma and milk, and lipid solubility, as well as milk composition. The milk-to-plasma concentration ratio is the most commonly quoted index of drug distribution into human milk. However, calculation of the daily infant dose of drug ingested in milk, and from this the dose in milk relative to the maternal dose on a weight-adjusted basis, is a more relevant indicator of infant exposure to a drug. This is particularly true for drugs with a high volume of distribution, for which only a small proportion of the mother's dose is contained within the plasma and available for distribution into milk. A better indication of infant exposure to a drug is the steady-state plasma drug concentration in a breast-feeding infant, the major determinants of which are the dose rate (via milk) and the oral availability and clearance in the infant. Although in neonates the rate of absorption may be different from adults, there is little evidence that its extent is significantly different. Clearance, however, is impaired in very young infants, particularly if premature. The decreased clearance would result in a proportional increase in steady-state plasma concentrations in the breast-feeding infant. Consideration of the dose ingested in milk and the approximate clearance in infants of different ages allows estimation of likely steady-state plasma concentrations in breast-feeding infants. From these considerations, recommendations regarding the safety of drugs during breast-feeding can be made. Drugs which are very toxic or have dose-independent toxicity should be considered separately. Recommendations regarding 'social' drugs such as nicotine, alcohol, caffeine and theobromine are particularly difficult, as doses are uncontrolled and vary variable.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292101     DOI: 10.2165/00003088-198814040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  227 in total

1.  d-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women.

Authors:  S Nilsson; K G Nygren; E D Johansson
Journal:  Am J Obstet Gynecol       Date:  1977-09-15       Impact factor: 8.661

2.  Digoxin excretion in human milk.

Authors:  J P Finley; M B Waxman; P Y Wong; G M Lickrish
Journal:  J Pediatr       Date:  1979-02       Impact factor: 4.406

3.  Placental and mammary transfer of sulphasalazine.

Authors:  A K Khan; S C Truelove
Journal:  Br Med J       Date:  1979-12-15

4.  Passage of pentobarbital and phenobarbital into bovine caprine milk after systemic administration.

Authors:  G E Miller; R D Peters; R V Engebretsen; C M Stowe
Journal:  J Dairy Sci       Date:  1967-05       Impact factor: 4.034

5.  Nicotine and cotinine concentrations in serum and urine of infants exposed via passive smoking or milk from smoking mothers.

Authors:  W Luck; H Nau
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

6.  Natural history of the fetal alcohol syndrome: a 10-year follow-up of eleven patients.

Authors:  A P Streissguth; S K Clarren; K L Jones
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

Review 7.  Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement.

Authors:  P C Walker
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

8.  Atenolol and metoprolol. A comparison of their excretion into human breast milk.

Authors:  J Kulas; N O Lunell; U Rosing; B Stéen; A Rane
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1984

9.  Analgesic drugs in breast milk and plasma.

Authors:  J W Findlay; R L DeAngelis; M F Kearney; R M Welch; J M Findlay
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

10.  Levonorgestrel in milk and plasma of breast-feeding women with a levonorgestrel-releasing IUD.

Authors:  M Heikkilä; M Haukkamaa; T Luukkainen
Journal:  Contraception       Date:  1982-01       Impact factor: 3.375

View more
  38 in total

Review 1.  Antibiotics and breast-feeding: a critical review of the literature.

Authors:  Allison M Chung; Michael D Reed; Jeffrey L Blumer
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 2.  Anticonvulsants and breast feeding: a critical review.

Authors:  B Bar-Oz; I Nulman; G Koren; S Ito
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

Review 3.  Antipsychotics and breast-feeding: a review of the literature.

Authors:  T Tényi; G Csábi; M Trixler
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

Review 4.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

5.  Use of sodium aurothiomalate during lactation.

Authors:  P N Bennett; S J Humphries; J P Osborne; A K Clarke; A Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 6.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

7.  Excretion of fluvoxamine in breast milk.

Authors:  S Wright; S Dawling; J J Ashford
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

8.  Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam.

Authors:  L J Dusci; S M Good; R W Hall; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 9.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.